Podcast Summary: Excess Returns
Episode: They Call It a Lottery Ticket. The Data Says Otherwise | D.A. Wallach on The Hidden Alpha of Biotech
Date: March 16, 2026
Host: Matt Zeigler (Excess Returns)
Guest: D.A. Wallach, Musician, Venture Capitalist, Co-Founder of Time BioVentures

Episode Overview

This episode of Excess Returns dives deep into the world of biotech investing—a sector often dismissed as a "lottery ticket" due to its high risk and uncertainty. Guest D.A. Wallach argues that, contrary to the lottery ticket narrative, skill and expertise can yield persistent alpha in biotech. The discussion spans biotech’s unique risk/reward structure, valuation challenges, portfolio construction, the changing capital environment, the role of specialists, the impact of AI, and global industry trends, especially China’s rising importance.

Key Discussion Points & Insights

1. Why Biotech Isn't Just a Lottery Ticket

• Biotech’s Unique Complexity:

  • Valuing biotech companies requires processing vast, domain-specific information that only true specialists can make sense of. Most market participants, quant or otherwise, lack the expertise to exploit these inefficiencies.
  • "The biotech hedge funds that basically drive most of the activity around these stocks are being paid by the market for the service that they're providing." (D.A. Wallach, 02:48)

• Nature of Uncertainty:

  • Development-stage biotech companies are typically pre-revenue, with success dependent on moving new drugs through years of highly uncertain, regulated trials.
  • The primary value in these companies is pinned to cash flows that may not materialize for 8–10 years, making them exceptionally sensitive to changes in interest rates and investor sentiment.

2. The “Bag of Options” and Valuation Framework

• Valuing Biotech Projects:

  • Early-stage biotech companies are best valued as a “bag of options”—each drug candidate represents a separate probabilistic path to eventual commercialization.
  • "A drug at that stage [preclinical] might have somewhere between a 5 and 10% chance of making it to the finish line." (D.A. Wallach, 03:54)
  • Analysts must project market size (TAM), calculate the net present value (NPV) of future potential revenues, and discount by the probability of regulatory and market success.

• Base Rates and Risk Assessment:

  • Estimating probabilities of success involves employing historical base rates for each stage—preclinical to phase 3—and adjusting for drug modality and other specifics.
  • "A lot of the art of biotech investing ... comes down to figuring out what are the right base rates to use for a given situation." (D.A. Wallach, 08:17)

3. Recent Market Cycles and Macro Headwinds

• Market Headwinds Post-Pandemic:

  • From 2021-2025, biotech suffered as rising interest rates reduced the present value of long-dated future cash flows, and capital fled to tech/AI “risk stories.”
  • "Big tech and the AI narrative created a competitor to biotech for that risk capital... money flowed out of the biotech sector into other parts of the market, and that just created a massive headwind for all of these companies" (Da Wallach, 13:31)
  • The sector experienced a recent resurgence mid-2025 as capital rotated back, leading to strong index-level returns.

• Pandemic Sugar High & Reset:

  • COVID-19 highlighted biotech’s central role but created a speculative bubble that quickly popped as enthusiasm waned and interest rates rose.
  • "Covid was a rude awakening because, you know, at the outset people were just desperate for a solution. The biotech industry ended up providing a pretty decent solution, but then that of course became itself highly contested." (Da Wallach, 17:44)

4. Specialist Investors and Industry Structure

• Role of Specialist Hedge Funds:

  • Biotech investing success is dominated by ~30-80 specialist hedge funds managing relatively small sums due to liquidity constraints in small/mid-cap stocks.
  • "None of them is that massive...some of the best players in this space have remained, even for a 20 or 30 year career, quite small." (D.A. Wallach, 24:26)
  • The ecosystem relies on private market innovation, IPOs, and large pharma M&A as the main engine for returns.

• Private vs. Public Biotech Investing:

  • Private biotech investors are often even more specialist and hands-on, sometimes co-building companies from inception—a notable difference from the norms in tech venture capital.
  • "In biotech, it's much more common that the venture capital firms will be quite involved with these entrepreneurs from the very inception of a company." (Da Wallach, 27:35)

5. Narrative vs. Reality in Biotech Investing

• Long Gestation and Faith in Narrative:
  • Unlike tech, where evidence of company traction surfaces quickly, biotech investments require years of waiting while only slow, difficult-to-interpret data emerges.
  • This underlies the importance of both scientific rigor and narrative-building.
  • "There's still so much narrative that it becomes especially important that you have contextualized a project...to signal to the market that it's on the path to success." (Da Wallach, 35:20)

6. The Role and Limits of AI in Biotech

• AI’s Potential and Hype:

  • AI is touted as transformative for drug discovery and development, prompting both real efficiency gains and narrative-driven flows.
  • In reality, AI is making incremental improvements in some workflows but is unlikely to bring overnight transformation.
  • "There is a superficial story...about AI is going to change everything. And that may over the long run be true. But what matters is what are the ways in which that transformation are investable." (Da Wallach, 36:55)

• Impact on Success Rates and Returns:

  • While better tech should raise success rates, the sector faces the problem that “all the low-hanging fruit” has been picked, and today's groundbreaking solutions target the most complex diseases.
  • "Everything we solve leaves us with harder things remaining to be solved, and that may work in the opposite direction." (Da Wallach, 39:27)

7. Portfolio Construction and Risk

• Diversification Approach:

  • A typical fund aims to make 20 bets per vintage, spread across different modalities, indications, and geographies to manage idiosyncratic risk.
  • "I just want a lot of colors and I don't want any one color to be too big where if it blew up, it would destroy me." (Da Wallach, 51:54)

• Volatility and “Volatility Laundering”:

  • Private markets mask portfolio volatility in early-stage biotech, since companies’ value is only re-marked during funding rounds—very different from daily public market price discovery.
  • "A preclinical biotech company is in fact only priced when it raises money." (Da Wallach, 48:22)

8. The Globalization of Biotech— Spotlight on China

• China’s Growing Role:
  • Increasingly, early clinical trials are run in China due to faster enrollment, high-quality scientists, and fewer obstacles—providing cost and speed advantages.
  • US ethnic diversity remains important for global regulatory approvals, but global thinking is imperative.
  • "It's imperative to think about it globally... Companies that engage in [outsourcing to China] are probably going to have a significant cost advantage." (Da Wallach, 57:11)

Notable Quotes & Memorable Moments

• "Making sense of biotech companies and valuing these companies requires processing a lot of very domain specific information. And that is still a type of work that only a small number of market participants are really expert at doing." — D.A. Wallach (02:48)
• "A drug at that stage might have some somewhere between a 5 and 10% chance of making it to the finish line." — D.A. Wallach (03:54)
• "A lot of the art of biotech investing that specialists like us are engaged in comes down to figuring out what are the right base rates to use for a given situation." — D.A. Wallach (08:17)
• "The key is to size your bets appropriately and have enough of them that you overcome those low individual odds for each individual company." — D.A. Wallach (46:25)
• "It's like free jazz because ... it's people who like risk, right? ... Most of the people in biotech are not in it for the money because if, if that's what they cared about, they wouldn't be doing this." — D.A. Wallach (67:13)

Timestamps for Important Segments

• Specialist edge and persistent alpha in biotech: 02:32–03:46
• Biotech companies as a “bag of options”: 03:46–08:09
• Base rates and risk assessment: 08:09–10:28
• Market cycle: post-pandemic drawdown and resurgence: 13:04–17:27
• Pandemic’s impact and aftermath: 17:27–20:16
• AI’s role in biotech (reality vs hype): 20:16–24:05; 36:15–39:27
• Specialists vs generalists in private & public biotech: 24:05–29:09
• Portfolio construction and diversification: 44:39–53:27
• China’s role in clinical trials: 53:27–58:32
• Investment philosophy—value vs. growth, systematizing: 58:32–66:25
• Biotech as a music genre/free jazz analogy: 66:25–68:45

Episode Takeaways

• Biotech’s “hidden alpha” is grounded in deep specialist knowledge and careful probabilistic thinking—not luck.
• This sector’s wild risk/return comes from the unpredictability of R&D, regulatory milestones, and long runways to revenue.
• Cycles in capital flows, interest rates, and narrative (e.g., COVID-19, AI) drive huge swings in sector fortunes.
• AI is stimulating real change, but it’s incremental and nuanced, not the overnight revolution often hyped.
• Diversification and patience are essential; specialists win by rigorous assessment of science and narrative.
• Globalization—especially China’s clinical landscape—will remain central to industry strategy and competitiveness.
• Ultimately, adaptability—being agnostic to style and open to changing market regimes—marks great investors in biotech and beyond.

Where to Learn More:

• D.A. Wallach: X/Twitter @DaWallach, dawallach.com, Substack
• Excess Returns Podcast: excessreturnspod.com

This summary captures the essential lessons, frameworks, and memorable moments from the conversation. For anyone considering biotech investing or seeking to understand where the sector stands—and the role of skill, narrative, and cyclicality—the episode offers a rich, pragmatic guide.